Press Releases NLS Pharmaceutics Ltd.

Equities

NLSP

CH0523961370

Delayed Nasdaq Other stock markets 16:05:39 13/05/2024 BST			5-day change	1st Jan Change
0.1326 ^USD	-4.81%		-2.50%	-77.52%

04-08	Nls Pharmaceutics Ltd. Announces Resignation of Anthony S. Walsh as A Member of the Board of Directors	CI
04-03	NLS Pharmaceutics Ltd. announced that it has received $1.75 million in funding	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

NLS Pharmaceutics : Various Claims Against the Company - Form 6-K	03-20	PU
NLS Pharmaceutics : SECOND ADDENDUM TO THE - Form 6-K	03-20	PU
NLS Pharmaceutics to Participate in the BIO-EUROPE Springtime Partnering Event	03-15	AQ
NLS Pharmaceutics Submits Plan to Regain Listing Compliance with Nasdaq	02-26	AQ
NLS Pharmaceutics - Notice of Deficiency with Nasdaq Continued Listing Requirements	01-15	AQ
Press release titled: “NLS Pharmaceutics CEO Issues Letter to Shareholders.” - Form 6-K	12-29	PU
NLS Pharmaceutics : Ordinary Shareholders’ Meeting Results - Form 6-K	12-22	PU
NLS Pharmaceutics : UNAUDITED INTERIM CONDENSED FINANCIAL STATEMENTS - Form 6-K	12-06	PU
NLS Pharmaceutics Announces Election of Additional Board Members	11-29	AQ
NLS Pharmaceutics to Participate in the Oppenheimer Sleep Disorders Summit, Deep Dive into Narcolepsy and Idiopathic Hypersomnia	11-28	AQ
NLS Pharmaceutics Announces Selection of Strategic Partner and Securing a Bridge Loan	11-17	AQ
NLS Pharmaceutics : Form 6-K	11-16	PU
NLS Pharmaceutics : Loan Agreement - Form 6-K	25/10/23	PU
NLS Pharmaceutics Announces Company Update Webcast	20/06/23	AQ
NLS Pharmaceutics : Invitation to the Ordinary Shareholders’ Meeting of NLS Pharmaceutics AG, Zurich, Switzerland - Form 6-K	09/06/23	PU
NLS Pharmaceutics : Receives Green Light from the U.S. FDA to Proceed with Phase 3 Clinical Program (AMAZE) for Quilience® (Mazindol ER) for the treatment of Narcolepsy - Form 6-K	02/05/23	PU
NLS Pharmaceutics : Amended and Restated Articles of Association - Form 6-K	21/02/23	PU
NLS Pharmaceutics : Invitation to the Extraordinary Shareholders’ Meeting of NLS Pharmaceutics Ltd., Zurich, Switzerland - Form 6-K	24/01/23	PU
NLS Pharmaceutics AG	23/01/23	AQ
NLS Pharmaceutics Announces an R&D Update Webcast to Review the Company's Growing Portfolio of Pre-Clinical Compounds	13/01/23	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases NLS Pharmaceutics Ltd.

Equities

NLSP

CH0523961370

Press Releases

Filters